| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.8 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | BIRB 0796 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | GW843682X | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |